Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2016
Editora
LIPPINCOTT WILLIAMS & WILKINS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
LIMA, Beatriz C. G. D.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
NUCLEAR MEDICINE COMMUNICATIONS, v.37, n.5, p.473-479, 2016
Resumo
ObjectivesThis study aimed to present a comparison of iodine-131 (I-131) biokinetics and radiation doses to red-marrow (rm) and whole-body (wb), following the administration of tracer and therapeutic activities, as a means of confirming whether I-131 clearance and radiation doses for therapy procedures can be predicted by tracer activities.MethodsEleven differentiated thyroid cancer patients were followed after receiving tracer and therapeutic I-131 activity. Whole-body I-131 clearance was estimated using radiation detectors and OLINDA/EXM software was used to calculate radiation doses to rm and wb.Results and discussionTracer I-131 activity of 86 (14)MBq and therapeutic activity of 8.04 (+/- 1.18)GBq were administered to patients, thereby producing an average wb I-131 effective half-time and residence time of, respectively, 13.51 (+/- 4.05) and 23.13 (+/- 5.98)h for tracer activities and 13.32 (+/- 3.38) and 19.63 (+/- 4.77)h for therapy. Radiation doses to rm and wb were, respectively, 0.0467 (+/- 0.0208) and 0.0589 (+/- 0.0207)mGy/MBq in tracer studies and 0.0396 (+/- 0.0169) and 0.0500 (+/- 0.0163)mGy/MBq in therapy. Although the differences were not considered statistically significant between averages, those between the values of effective half-times (P=0.906), residence times (P=0.145), and radiation doses to rm (P=0.393) and to wb (P=0.272), from tracer and therapy procedures, large differences of up to 80% in wb I-131 clearance, and up to 50% in radiation doses were observed when patients were analyzed individually, thus impacting on the total amount of I-131 activity calculated to be safe for application in individual therapy.Conclusion(131)I biokinetics and radiation doses to rm and wb in therapy procedures are well predicted by diagnostic activities when average values of a group of patients are compared. Nonetheless, when patients are analyzed individually, significant differences may be encountered, thus implying that nuclear medicine therapy-planning requires due consideration of changes in individual patient-body status from initial tracer to final therapy procedures to thus provide appropriate adjustments in therapeutic activities.
Palavras-chave
biokinetics, dosimetry, I-131 therapy, therapy planning, thyroid cancer
Referências
- Choksi NY, 2003, BIRTH DEFECTS RES B, V68, P479, DOI 10.1002/bdrb.10045
- Mazzaferri EL, 2002, ENDOCR-RELAT CANCER, V9, P227, DOI 10.1677/erc.0.0090227
- Willegaignon J, 2006, HEALTH PHYS, V91, P624, DOI 10.1097/01.HP.0000225467.10064.34
- Sgouros G, 2006, J NUCL MED, V47, P1977
- Stabin MG, 2005, J NUCL MED, V46, P1023
- Woolfenden JM, 2006, J NUCL MED, V47, P1403
- Silberstein EB, 2012, J NUCL MED, V53, P1633, DOI 10.2967/jnumed.112.105148
- Duranton Flore, 2013, Clin Kidney J, V6, P478, DOI 10.1093/ckj/sft092
- Willegaignon J, 2012, RADIAT PROT DOSIM, V149, P138, DOI 10.1093/rpd/ncr214
- WALSER M, 1965, J CLIN INVEST, V44, P1371, DOI 10.1172/JCI105242
- BRICKER NS, 1955, J CLIN INVEST, V34, P1057, DOI 10.1172/JCI103155
- Willegaignon J, 2006, HEALTH PHYS, V91, P119, DOI 10.1097/01.HP.0000202232.98823.87
- Dorn R, 2003, J NUCL MED, V44, P451
- Song H, 2006, J NUCL MED, V47, P1985
- SCHLUMBERGER M, 1980, J CLIN ENDOCR METAB, V51, P513
- Remy H, 2008, J NUCL MED, V49, P1445, DOI 10.2967/jnumed.108.052464
- Sisson JC, 2003, J NUCL MED, V44, P898
- Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110
- Luster M, 2008, EUR J NUCL MED MOL I, V35, P1941, DOI 10.1007/s00259-008-0883-1
- Lassmann M, 2008, EUR J NUCL MED MOL I, V35, P1405, DOI 10.1007/s00259-008-0761-x
- BEYER KH, 1981, J CLIN PHARMACOL, V21, P201
- Sisson JC, 2006, J NUCL MED, V47, P1406
- Hindorf C, 2010, EUR J NUCL MED MOL I, V37, P1238, DOI 10.1007/s00259-010-1422-4
- Sisson JC, 2011, THYROID, V21, P335, DOI 10.1089/thy.2010.0403
- Clark WF, 2011, CLIN J AM SOC NEPHRO, V6, P2634, DOI 10.2215/CJN.01990211
- DeNardo DA, 1996, J NUCL MED, V37, P1970
- McDougall IR, 2011, SEMIN NUCL MED, V41, P105, DOI 10.1053/j.semnuclmed.2010.10.004
- Rosário Pedro Weslley S do, 2006, Arq Bras Endocrinol Metabol, V50, P91